Stirred, shaken, or stagnant: What goes on at the blood-biomaterial interface

Abstract There is a widely recognized need to improve the performance of vascular implants and external medical devices that come into contact with blood by reducing adverse reactions they cause, such as thrombosis and inflammation. These reactions lead to major adverse cardiovascular events such as...

Full description

Saved in:
Bibliographic Details
Published in:Blood reviews 2017-01, Vol.31 (1), p.11-21
Main Authors: Reviakine, Ilya, Jung, Friedrich, Braune, Steffen, Brash, John L, Latour, Robert, Gorbet, Maud, van Oeveren, Wim
Format: Article
Language:English
Subjects:
Animals
Antiplatelet therapy
Biocompatible Materials - standards
Biocompatible Materials - therapeutic use
Biomaterials
Biomimetic Materials - standards
Biomimetic Materials - therapeutic use
Blood Coagulation
Blood Platelets - drug effects
Blood Platelets - metabolism
Cardiovascular Diseases - blood
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - surgery
Cardiovascular implants
Coagulation
Hematologic Tests
Hematology, Oncology and Palliative Medicine
Hemocompatibility
Humans
Platelets
Prostheses and Implants - adverse effects
Prostheses and Implants - standards
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract There is a widely recognized need to improve the performance of vascular implants and external medical devices that come into contact with blood by reducing adverse reactions they cause, such as thrombosis and inflammation. These reactions lead to major adverse cardiovascular events such as heart attacks and strokes. Currently, they are managed therapeutically. This need remains unmet by the biomaterials research community. Recognized stagnation of the blood-biomaterial interface research translates into waning interest from clinicians, funding agencies, and practitioners of adjacent fields. The purpose of this contribution is to stir things up. It follows the 2014 BloodSurf meeting (74th International IUVSTA Workshop on Blood-Biomaterial Interactions), offers reflections on the situation in the field and a three-pronged strategy integrating different perspectives on the biological mechanisms underlying blood-biomaterial interactions. The success of this strategy depends on reengaging clinicians and on the renewed cooperation of the funding agencies to support long-term efforts.
ISSN:0268-960X
1532-1681
DOI:10.1016/j.blre.2016.07.003